Australia is eagerly awaiting the arrival of retatrutide, a groundbreaking dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, https://giant-bikes-cypress805710.kisa-blog.com/312683/novo-nordisk-s-retatrutide-australia-a-potential-hope-for-weight-management